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Introduction: Trenonacog alfa (IB1001) is a recombinant factor IX (rFIX) manufactured 
in Chinese hamster ovary (CHO) cells. IB1001 was evaluated in a multicentre clinical 
trial with haemophilia B patients.
Aim: The aim was to establish IB1001 pharmacokinetic non- inferiority to comparator 
rFIX, safety and efficacy in previously treated patients (PTPs) with haemophilia B.
Methods: Subjects were severe or moderately severe haemophilia B adult and adoles-
cent PTPs with no history of FIX inhibitors.
Results: IB1001 PK non- inferiority to comparator rFIX was demonstrated through 
ratio of AUC0-∞ in 32 subjects. IB1001 was well tolerated in all 76 treated sub-
jects; the most common adverse drug reaction was headache (2.6% of subjects) 
and there were no reports of FIX inhibitors. Transient non- inhibitory binding FIX 
antibodies and anti- CHO cell protein antibodies developed in 21% and 29% of 
subjects respectively; no safety concerns were associated with development of 
these antibodies. Prophylaxis (mean duration ± SD: 17.9 ± 9.6 months, mean 
dose: 55.5 ± 12.9 IU/kg, median 1.0 infusion per week) was effective in prevent-
ing bleeds (median annual bleed rate: 1.52, interquartile range: 0.0- 3.46). One or 
two IB1001 infusions resolved 84% of the bleeds, while for 84% of treatments 
haemostatic efficacy of IB1001 was rated excellent or good. IB1001 haemostatic 
efficacy for all 19 major surgeries was rated adequate or better than adequate.
Conclusions: IB1001 is safe and efficacious for treatment of bleeds, routine prophy-
laxis and perioperative management in haemophilia B patients.
K E Y W O R D S
efficacy, haemophilia B, IB1001, pharmacokinetics, recombinant factor IX, safety
1  | INTRODUCTION
Haemophilia B is an X- linked recessive bleeding disorder caused by 
a deficiency of coagulation factor IX.1 Severe forms of haemophilia B 
present in early life, at circumcision, or with joint and soft tissue bleeds 
when the child becomes mobile. Mild cases may present following 
haemostatic challenges such as surgery or trauma. Internal bleeding 
may occur anywhere and bleeding into joints is common.2
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Haemophilia B is treated by infusion of FIX concentrate. Despite 
substantial improvements in the safety of plasma- derived coagulation 
factor concentrates recombinant products are currently considered 
to be optimum treatment.3 Several recombinant versions of FIX have 
been marketed for treatment of haemophilia B2 including standard 
half- life products and extended half- life products.
Trenonacog alfa (IB1001) is a standard half- life rFIX produced in 
a genetically engineered Chinese hamster ovary (CHO) cell line with 
no exogenous materials of human or animal origin used in the manu-
facture, purification, or formulation of the final product. The primary 
amino acid sequence of IB1001 contains a threonine at residue 148, 
in contrast to other available conventional half- life recombinant FIX 
products that have an alanine at that position.4 The manufactur-
ing process includes three independent viral removal/inactivation 
steps: solvent/detergent treatment, a chromatographic step and 
nanofiltration.
A Phase 3 controlled, multicentre study was designed to evaluate 
PK non- inferiority of IB1001 to a comparator standard half- life rFIX, 
as well as to establish safety and haemostatic efficacy of IB1001 in ad-
olescent	and	adult	(≥12	years	of	age)	severe	(FIX	activity	<1	IU/dL)	and	
moderately	 severe	 (FIX	 activity	 ≤2	IU/dL)	 haemophilia	 B	 previously	
treated patients with severe bleeding phenotype. Based on the results 
of this study, IB1001 was licensed in the United States as IXINITY® 
(coagulation factor IX [recombinant]) for prevention and control of 
bleeding episodes, and for perioperative management in adults and 
children	≥12	years	of	age	with	haemophilia	B.
2  | MATERIAL AND METHODS
2.1 | Study design
The study included a PK Phase that was a randomized, double- blinded 
cross- over comparison of IB1001 to a marketed rFIX comparator 
(nonacog alfa). Following a 5- day wash out period, subjects received 
75 ± 5 IU/kg of the first treatment after which there was another 
5- day wash out period before receiving the second treatment. There 
was also a repeat open- label, uncontrolled PK phase in a subset of pa-
tients that participated in the initial PK Phase. After at least 3 months 
of receiving IB1001, these subjects received an infusion of 75 ± 5 
IU/kg of IB1001 prior to PK assessment.
The study also consisted of an open- label Treatment Phase 
in which patients received IB1001 either as prophylaxis or on- 
demand, with a goal of acquiring 50 exposure days (ED) for pro-
phylaxis patients or 6 months on study for on- demand patients. 
Patients from the PK Phase could transition into the Treatment 
Phase or patients could enter the Treatment Phase directly after 
performing a recovery assessment with IB1001. Patients on pro-
phylaxis were recommended a dose of 50- 75 IU/kg, twice weekly 
based on investigator discretion. Patients receiving on demand 
treatment received a recommended dose of 50- 100 IU/kg de-
pending on the severity of the bleeding episode. Following com-
pletion of the Treatment Phase, patients could continue in an 
open- label Continuation Phase. During the Continuation Phase, 
some subjects were found to have a high anti- CHOP antibody 
titre. As a result, an additional hydrophobic interaction chroma-
tography step was validated for use in the IB1001 manufacturing 
process to reduce content of host cell proteins in the final drug 
product (ie, modified IB1001). Results of a non- clinical study com-
paring the previous IB1001 product and modified IB1001 showed 
that the modified process significantly reduced the immunogenic 
potential of IB1001.5 The PK, safety, efficacy, and immunogenicity 
data in this manuscript are derived from IB1001 manufactured be-
fore this process change.
In addition, there was an open- label surgical sub- study that as-
sessed IB1001 efficacy for perioperative management. Subjects re-
ceived IB1001 by either bolus infusions or continuous infusion. The 
bolus infusion regimen consisted of an infusion of IB1001 up to 
120 IU/kg 1 hour prior to the start of surgery, followed by 60 IU/kg 
every 12 hours for at least 3 days postsurgery. The continuous infu-
sion regimen consisted of a bolus infusion of up to 120 IU/kg 1 hour 
prior to the start of surgery followed by continuous infusion of IB1001 
with a target plasma FIX level between 70 and 110 IU/dL.
The study (clinicaltrials.gov number: NCT00768287) was run 
from February 10, 2009 until March 1, 2013 in accordance with the 
Declaration of Helsinki and was approved by local independent ethics 
committees for 23 sites in 7 countries throughout North America (US), 
Europe (UK, Italy, France, Poland), Middle East (Israel) and Asia (India). 
All patients provided informed consent prior to enrolment.
2.2 | Patient population
Eligible subjects included immunocompetent adolescents and adults 
(≥12	years	 of	 age)	 with	 documented	 severe	 (FIX	 activity	 <1	IU/dL)	
or	moderately	severe	(FIX	activity	≤2	IU/dL)	haemophilia	B,	who	had	
previously been treated with a FIX concentrate for at least 150 ED 
with no history of FIX inhibitors. On a country- specific basis, subjects 
<12	years	of	age	were	able	to	enter	the	study	at	the	treatment	phase.	
On- demand patients had a minimum of 3 bleeds requiring treatment 
within 6 months prior to enrolment or 6 bleeds over the preceding 
12 months; subjects on prophylaxis had to have this bleeding pattern 
prior to starting prophylaxis.
2.3 | Pharmacokinetic assessments
The primary objective of the PK Phase was to evaluate PK non- 
inferiority of IB1001 to marketed standard half- life rFIX compara-
tor (nonacog alfa). Factor IX activity levels using a one- stage clotting 
assay at a central laboratory were the basis for all PK parameter com-
putations. Samples were taken pre- infusion and at the following time 
points post- infusion: 30 minutes ± 5 minutes, 1 hour ± 5 minutes, 
3 hours ± 30 minutes, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 
2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 
60 hours ± 3 hours, and 72 hours ± 3 hours. The following PK 
parameters were computed per actual dose administered for IB1001 
and the comparator rFIX: area under curve (AUC), referring to area 
under the plasma concentration vs time curve, at 0- 72 hours (AUC0-72 h) 
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and 0 to infinity (AUC0-∞), maximum plasma concentration (Cmax), clear-
ance, mean residence time (MRT), terminal half- life (t1/2), incremental 
recovery and volume of distribution at steady state (Vdss).
2.4 | Haemostatic efficacy
The haemostatic efficacy of IB1001 was evaluated by calculation of 
annualized bleed rate (ABR) for prophylaxis subjects and the number 
of infusions used to treat a bleed and overall rating of efficacy by 
subjects and investigators or surgeons (Table 1). Compliance to pro-
phylactic regimen was calculated as the total number of IB1001 infu-
sions administered, divided by the total expected number of IB1001 
infusions, multiplied by 100. Investigator efficacy assessments were 
performed every 3 months.
2.5 | Perioperative haemostatic efficacy
The ability of IB1001 to provide adequate haemostasis during major 
surgeries was evaluated in the surgery sub- study. Blood loss at time 
of surgery and at 12 and 24 hours postsurgery were used to evaluate 
haemostatic efficacy of IB1001.
2.6 | Immunogenicity
Testing for FIX inhibitors was performed using a modified Nijmegen 
Bethesda assay in a central laboratory. The presence of non- 
neutralizing FIX binding antibodies and non- neutralizing anti- CHO 
cell protein (CHOP) antibodies was also tested in the central labora-
tory with enzyme- linked immunosorbent assays (ELISA) employing 
polyclonal anti- human Ig antibodies (IgG, IgM and IgA) adapted for 
detection of anti- FIX or anti- CHOP antibodies. If samples tested posi-
tive for anti- CHOP antibodies, they were further assessed to deter-
mine the titre.
2.7 | Safety assessments
Safety was evaluated through reports of adverse events (AEs), hae-
matology, blood chemistry, physical examinations and vital signs 
at each study visit. The same safety assessments were conducted 
in study subjects that transitioned to modified IB1001 (ie, study 
drug manufactured with a modified process to reduce host cell 
proteins).
2.8 | Statistical analysis
A comparison of IB1001 and nonacog alfa was based on two- sided 
90% confidence interval (CI) for the AUC0-∞ ratio of IB1001 over 
nonacog alfa (calculated on a log scale and then untransformed). The 
within- group standard deviation was determined using the pooled 
result for the 2 groups. Non- inferiority of IB1001 compared to nona-
cog alfa was declared if the lower bound of the 90% CI for the ratio 
of AUC0-∞ for IB1001/nonacog alfa was >0.80. All other PK parame-
ters between IB1001 and nonacog alfa were reported as descriptive 
statistics. PK data from this study has been published previously;6 
however, a different software (WinNonlin) was used to derive the 
PK parameters for this manuscript and an additional subject was in-
cluded in repeat PK analysis. The ABR was calculated as: (number 
of bleeding episodes × 12)/(observed treatment period in months). 
Since subjects were allowed to switch treatment regimens while on 
study, the efficacy analysis is based on the actual regimen.
TABLE  1 Rating scale of haemostatic efficacy
Subject rating
Excellent A dramatic response with abrupt pain relief and clear reduction in joint or haemorrhage site size
Good Pain relief or reduction in haemorrhage site size that may have required an additional infusion for resolution
Fair Probable or slight beneficial response usually requiring one or more additional infusions for resolution
Poor No improvement or condition worsens
Investigator rating
Effective Each bleeding episode treated in the interval was evaluated by the subject as either “excellent” or “good” at the 
majority of time points
Partially effective Bleeding episodes treated in the interval were evaluated as either “excellent”, “good”, or “fair” at the majority of 
time points; or 1 bleeding episode received an evaluation of “poor” at the majority of time points
Not effective More than one- third of bleeding episodes during the interval were evaluated as “poor” at the majority of time points
Not applicable No bleeding episodes during the interval
Surgeon rating
Less than expected Blood loss estimate at time of surgery
Expected
More than expected
Haemostasis superior Blood loss assessment at 12 and 24 h postsurgery
Haemostasis adequate
Haemostasis poorly controlled
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3  | RESULTS
3.1 | Study patient population
A total of 76 subjects were enrolled and received at least one infu-
sion of IB1001 (Figure 1). Patient demography is presented in Table 2. 
The mean age was 30.5 years (median: 26; min, max: 7, 64). There 
were	3	 subjects	<12	years	of	 age	who	 received	waivers	 to	enrol	 in	
the treatment phase of the study. Most of the subjects were severe 
(14.5%) or moderately severe (81.6%) haemophilia B males. Median 
number of bleeding episodes within 6 months prior to enrolment was 
1.0 (min, max: 0.0, 21.0) and the majority of subjects had arthropathy 
and target joints at screening. All subjects were treated with FIX re-
placement therapy prior to enrolment. There were 32 subjects that 
completed the PK Phase and following completion of the PK Phase, 
29 of those subjects continued into the Treatment Phase (14 of these 
F IGURE  1 Overview of subject disposition
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subjects underwent a repeat PK evaluation), while 41 subjects directly 
entered the Treatment Phase after an initial recovery assessment. At 
the start of Treatment Phase, 58 subjects elected prophylaxis and 9 
subjects chose an on- demand regimen. For surgical sub- study, there 
were 16 subjects that underwent 19 major surgeries.
3.2 | Pharmacokinetic parameters
The lower bound 90% CI for ratio of AUC0-∞ for IB1001/nonacog alfa 
was 0.89 demonstrating that the primary PK endpoint criterion of 
>0.80 was met. Other PK parameters between the two rFIX products 
were comparable (Table S1). The repeat PK analysis demonstrated the 
stability of initial PK parameters during long- term exposure (median: 
5.8 months; min, max: 3.1, 18 months) to IB1001 (Table S1).
3.3 | Haemostatic efficacy
Most of the subjects (37/61) who treated prophylactically in the 
Treatment/Continuation phases of the study fulfilled the criteria for 
secondary or tertiary prophylaxis as defined in the WFH guidelines.4 
However, subjects were allowed to switch regimens at discretion 
of the investigator and the subject; therefore, the analysis of effi-
cacy includes data based on the actual treatment regimen followed. 
In total, there were 61 subjects who received prophylaxis and 12 
subjects who received on- demand regimen. Compliance to prophy-
lactic treatment was 88% (median; Table 3). The summary of IB1001 
treatment and ABR for prophylaxis and on- demand cohorts is pre-
sented in Table 4. The mean ± SD duration of treatment for proph-
ylaxis subjects was 17.9 ± 9.6 months (median: 16.2; min, max: 2.4, 
39.6), with a mean dose of 55.5 ± 12.8 IU/kg (median: 53; min, max: 
26, 80) and a mean of 1.9 infusions per week (median: 1.0; min, max: 
1.0, 2.0). For on- demand subjects, mean duration of treatment was 
15.9 ± 11.5 months (median: 14.1; min, max: 2.3, 36.9), with a mean 
dose of 60.0 ± 18.2 IU/kg (median: 59; min, max: 24, 94). The over-
all mean exposure to IB1001 was 183 ± 91 ED (median: 127.5; min, 
max:	1,	 430);	 there	were	55	 subjects	with	≥50	ED	and	45	 subjects	
with	≥100	ED.	For	prophylaxis	subjects,	the	mean	exposure	to	IB1001	
was 149 ± 93 ED (median: 136; min, max: 1, 430) and for on- demand 
subjects it was 84 ± 35 ED (median: 94; min, max: 40, 131). As ex-
pected, the ABR for prophylaxis group (median: 1.52; IQR: 0.0- 3.46) 
was lower when compared to on- demand ABR (median: 16.1; IQR: 
6.60- 23.71) (Table 3).
A total of 508 bleeding episodes were treated with IB1001 (286 
reported by 42/61 prophylaxis subjects and 222 bleeding episodes 
reported by 10/12 on- demand subjects). There were 426 bleeding 
episodes (84%) that resolved with one or two IB1001 infusions (71% 
of bleeding episodes were resolved with one infusion; the majority 
of these [59%] were joint haemorrhages). For 24 bleeding episodes 
TABLE  2 Demography characteristics of study subjects
Demography 
parameter
Initial PK 
crossover  
N = 32
Repeat PK  
N = 14
Treatment/continuation phase
Surgery 
sub- study  
N = 16
Overall  
N = 76
Prophylaxis 
N = 58
On- demand 
N = 9
Gender n (%)
Male 32 (100.0) 14 (100.0) 58 (100.0) 9 (100.0) 16 (100) 76 (98.7)
Female 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Age (y)
Mean ± SD 32.7 ± 15.0 31.5 ± 16.5 28.8 ± 14.2 36.4 ± 10.9 31.5 ± 12.4 30.5 ± 14.4
Median (min- max) 29.9 (14.8- 64.5) 25.4 (15.3- 65.8) 23.3 (7.4- 64.5) 39.4 (19.1- 48.9) 32.6 (12.2- 56.8) 26.0 (7.0- 64.0)
Race n (%)
American Indian/
Alaskan Native
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Asian 0 (0.0) 0 (0.0) 7 (12.1) 0 (0.0) 5 (31.3) 8 (10.5)
Black or African 
American
1 (3.1) 0 (0.0) 3 (5.2) 0 (0.0) 1 (6.3) 3 (3.9)
Caucasian 30 (93.8) 13 (92.9) 44 (75.9) 9 (100.0) 9 (56.3) 60 (78.9)
Native Hawaiian/
Pacific Islander
0 (0.0) 0 (0.0) 2 (3.4) 0 (0.0) 0 (0.0) 2 (2.6)
Other 1 (3.1) 1 (7.1) 2 (3.4) 0 (0.0) 1 (6.3) 3 (3.9)
Baseline FIX activity (% FIX activity) n (%)
<1% 11 (14.5)
1- 2% 62 (81.6)
>2% 3a (3.9)
a3	subjects	had	FIX	activity	>2%	at	baseline	after	the	wash-	out	period,	however	all	3	subjects	in	their	medical	history	had	records	of	FIX	activity	<2%,	as	
well as symptoms consistent with severe form of haemophilia B, therefore these 3 subjects were deemed eligible for study enrollment.
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(4.7%) that were predominantly related to trauma, target joints, or 
muscle bleeds, 5 or more infusions were required.
Haemostatic efficacy at bleed resolution was rated by the subjects 
as “excellent” or “good” in 84% of all treated bleeds. Overall, IB1001 
haemostatic efficacy was rated as “effective” 92% of the times by the 
investigators, with 8% rated as “partially effective.” None of the inves-
tigator ratings were reported as “not effective.”
3.4 | Perioperative haemostatic efficacy
Surgery sub- study involved 16 subjects who underwent 19 evalu-
able major surgeries; IB1001 was administered as bolus infusions 
in 13 procedures or as continuous infusion in 6 procedures. Mean 
loading bolus dose prior to the surgical procedure was 120 ± 11.4 
IU/kg (median: 120 IU/kg, min- max: 103.2, 142 IU/kg). Maintenance 
bolus infusions were given every twelve hours and the corresponding 
mean maintenance bolus dose was 59.7 ± 12.2 IU/kg (median 60 IU/
kg; min- max: 23.8, 120.0 IU/kg), as dictated by the subject’s needs. 
For procedures managed by continuous infusions, subjects first re-
ceived a mean loading dose of 95.4 ± 14.5 IU/kg (median 99.1 IU/
kg; min- max: 67.2- 109.0 IU/kg), followed by a mean continuous infu-
sion of 7.1 ± 4.0 IU/kg h−1 (median 6.9 IU/kg h−1; range: 3.0, 21.5 IU/
kg h−1). Blood loss at the time of surgery was rated by the surgeon as 
“expected” (n = 6) or “less than expected” (n = 13), while at 12 and 
24 hours postsurgery IB1001 was rated by the surgeon as “superior” 
(n = 7) or “adequate” (n = 12) in controlling haemostasis. There were 
no transfusion requirements during the surgical procedures (Table 4).
3.5 | Safety
IB1001 appeared well tolerated in all 76 study subjects exposed. 
There were no deaths, severe allergic reactions, anaphylaxis, throm-
boembolic events or related serious adverse events (SAEs). A total of 
444 AEs were reported by 57/76 subjects (75%), including 15 AEs 
in 7 subjects (9%) that were considered related to IB1001 treatment 
or adverse drug reactions (ADRs, Table 5). The most common ADR 
was headache [5 events in 2 subjects (2.6%)]. None of the subjects 
developed FIX inhibitors during the study, while 16/77 (21%) subjects 
developed non- neutralizing FIX antibodies after screening. After re-
ceiving IB1001, 68 subjects have been tested for anti- CHOP reactiv-
ity; 20 subjects (29%) seroconverted (developed persistent anti- CHOP 
reactivity), 37 subjects (54%) remained negative, while 11 subjects 
(16%) were considered indeterminate (2 subjects were positive at 
screening, 5 subjects had persistent non- specific antibody binding, 3 
subjects had an isolated positive test result and one subject had no 
sufficient follow- up samples). There were no safety concerns related 
to development of non- neutralizing FIX antibodies or anti- CHOP an-
tibodies. After at least 12 months of treatment with modified IB1001, 
there were no new seroconversions in previously anti- CHOP nega-
tive subjects (n = 10) or in subjects (n = 3) with indeterminate assay 
results (ie, reactive for non- specific assay control). Two subjects with 
anti- CHOP titres demonstrated negative anti- CHOP results after 
≥12	months	of	modified	IB1001	treatment,	while	the	other	2	subjects	
had stable  titres (Table S2).
4  | DISCUSSION
This was the first clinical trial with IB1001 (trenonacog alfa), a stand-
ard half- life rFIX. The results of the PK Phase demonstrated IB1001 
PK non- inferiority to the comparator rFIX, and IB1001 incremental 
recovery of 0.98 ± 0.21 IU/dL.
Prophylactic treatment and in particular early prophylaxis has been 
associated with reduction in bleeding episodes.7,8 In this clinical trial, 61 
subjects received routine prophylaxis (median duration: 16.2 months), 
of which 19 subjects (31%) reported no bleeding episodes. In addition, 
there were 12 on- demand subjects (median duration: 16.1 months) 
in the study. The dose ranges used to treat bleeding episodes in this 
study (50- 100 IU/kg) are similar to the dosing recommendations for 
TABLE  3 Summary of IB1001 treatment and annualized bleed 
rate (ABR)
Prophylaxis  
N = 61
On- demand 
N = 12
Treatment duration (mo)
Mean ± SD 17.9 ± 9.6 15.9 ± 11.5
25th percentile 9.2 5.5
Median (min- max) 16.2 (2.4- 39.6) 14.1 (2.3- 36.9)
75th percentile 24.2 25.2
Number of exposure days
Mean ± SD 148.8 ± 93.1 84.2 ± 34.7
Median (min- max) 135.5 (1- 430) 94.0 (40- 131)
Number of infusions per wk
Mean ± SD 1.9 ± 2.2 Not applicable
25th percentile 1
Median (min- max) 1.0 (1.0- 20.0)
75th percentile 2
Dose per infusion (IU/kg)
Mean ± SD 55.0 ± 12.8 60.0 ± 18.2
25th percentile 49.9 49.9
Median (min- max) 53.0 (26.1- 80.2) 59.3 (23.9- 94.1)
75th percentile 64.0 71.8
Total ABR
Mean ± SD 3.55 ± 7.19 16.39 ± 11.83
25th percentile 0.00 6.60
Median (min- max) 1.52 (0.0- 47.5) 16.10 (0.0- 39.4)
75th percentile 3.46 23.71
Patients with zero 
bleeds n (%)
19 (31.1) Not applicable
Compliance
Mean ± SD 87.7 ± 11.9% Not applicable
Median (min- max) 90.3% 
(53.4%- 103.0%)
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major bleeds with both nonacog alfa and nonacog gamma, which 
target a circulating FIX level of 50- 100 IU/dL and are also consistent 
with WFH guidelines2 for moderate bleeds (circulating FIX level of 
40- 60 IU/dL) and major bleeds (circulating FIX level of 80- 100 IU/dL). 
As expected, the ABR of prophylaxis cohort (median: 1.52) was lower 
when compared to the ABR of on- demand cohort (median: 16.10). 
This is consistent with the previously published data on rFIX ther-
apy.9,10 The percentage of subjects with baseline FIX levels 1- 2 IU/dL 
is 81%, which is higher than in other studies, although all subjects in 
this study had a severe bleeding phenotype prior to study entry.
Haemostatic efficacy of IB1001 was evaluated in the Treatment 
and Continuation phases of the study. Of the 508 bleeding episodes, 
regardless of treatment regimen or type of bleeding episode (ie, spon-
taneous or due to trauma) where IB1001 efficacy was rated by sub-
jects, the efficacy was considered “good” or “excellent” 84% of the 
time. The majority of bleeds (84%) were resolved with one to two 
IB1001 infusions, similar to results derived from studies with other 
standard half- life rFIX products.9,11
Perioperative haemostatic efficacy of IB1001 was evaluated in 16 
subjects who underwent 19 major surgeries, including 13 surgeries 
supported by bolus IB1001 infusions and 6 surgeries supported by 
continuous infusion. The dosing FIX trough target of >60 IU/dL in 
this study is less than the recommended target for nonacog gamma 
(80- 100 IU/dL), but is consistent with the WFH guidelines which tar-
get 60- 80 IU/dL preoperatively and then range from 20 to 60 IU/dL 
postoperatively. For all 19 major surgeries, the surgeon’s assessment 
of blood loss at the time of surgery was “less than expected” or “ex-
pected”. Consistent with this, haemostasis postsurgery was considered 
“superior” (n = 6) or “adequate” (n = 13) at 12 and 24 hours postsur-
gery. Across the subjects’ procedures, there was no consistent pattern 
between the ratings at the time of surgery and the postsurgery ratings. 
However, all ratings of haemostasis with IB1001 at the time of surgery 
were at least “expected” and all ratings postsurgery were at least “ad-
equate” when compared to similar procedures in non- haemophilic pa-
tients. This is supported by the lack of transfusion requirements during 
the procedures.
IB1001 was well tolerated as there were no reports of deaths, al-
lergic reactions, anaphylaxis, thromboembolic events or related SAEs. 
The most common ADR was headache (2.6% of subjects). There were 
no reports of FIX inhibitors at any point during the study. Some subjects 
(21%) developed transient non- inhibitory binding FIX antibodies with 
no apparent effect on subject safety or efficacy of IB1001. Presence 
of non- inhibitory binding FIX binding antibodies has been reported in 
haemophilia B patients treated with FIX replacement therapy,12 albeit 
the clinical significance is unknown. Antibodies to CHO cell proteins 
have been previously reported with CHO cell- derived recombinant 
factor concentrates.13,14 In this study, 20/68 subjects (29%) tested 
positive for anti- CHOP antibodies with no apparent effect on subject 
safety or efficacy of IB1001. The ongoing study subjects (n = 17) in 
the Continuation Phase were then transitioned to modified IB1001; 
after	 ≥12	months	of	 treatment	with	modified	 IB1001	no	new	 sero-
conversions were observed in previously anti- CHOP negative subjects 
TABLE  4 Summary of perioperative haemostatic IB1001 efficacy
Type of major 
surgical procedure
Number of 
procedures 
N = 19
Type of 
IB1001 dosing
Perioperative haemostasis assessment
Requirement 
for transfusion 
(yes/no)
At time of surgery 
(number of 
procedures)
12 h postsurgery 
(number of 
procedures)
24 h postsurgery 
(number of 
procedures)
Knee arthroplasty 5 Bolus Expected (5) Superior (1) Superior (1) No
Adequate (4) Adequate (4)
3 CI Expected (3) Superior (1) Superior (1)
Adequate (2) Adequate (2)
Knee amputation 1 Bolus Expected (1) Superior (1) Superior (1) No
Elbow arthroplasty 2 CI Less than expected (2) Superior (1) Superior (1) No
Adequate (1) Adequate (1)
Arthroscopic 
synovectomy
2 Bolus Less than expected (1) Adequate (2) Adequate (2) No
Expected (1)
Ankle debridement 2 Bolus Less than expected (1) Superior (1) Superior (1) No
Expected (1) Adequate (1) Adequate (1)
Knee debridement 1 Bolus Expected (1) Superior (1) Superior (1) No
Percutaneous 
Achilles tendon 
lengthening
1 CI Expected (1) Adequate (1) Adequate (1) No
Open inguinal 
hernia repair
1 Bolus Less than expected (1) Superior (1) Superior (1) No
Tibiotalar fusion 1 Bolus Less than expected (1) Adequate (1) Adequate (1) No
CI, continuous infusion.
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(n = 10). Two out of 4 subjects with anti- CHOP titres reverted to anti- 
CHOP negative status, while the other 2 subjects had stable titres. 
Overall, these results may indicate that the anti- CHOP immunogenic-
ity potential of modified IB1001 has been reduced with the addition of 
the validated step to IB1001 manufacturing process.
5  | CONCLUSION
The non- inferior PK profile of IB1001 to nonacog alfa, the generally 
positive assessment of control and treatment of breakthrough and 
other bleeding episodes during the Treatment/Continuation phase 
by both patients and investigators, and the uniformly positive assess-
ments of haemostatic adequacy or superiority of IB1001 for periop-
erative management of major surgeries, provide strong evidence of 
the efficacy of IB1001 for the control, prevention, and reduction in 
bleeding in subjects with haemophilia B. The lack of significant safety 
findings, specifically lack of any detected FIX inhibitors and all other 
serious class specific adverse events provide support that the safety 
profile of IB1001 is acceptable for treatment of subjects with haemo-
philia B.
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MedDRA standard system 
organ class
Adverse drug 
reactiona
No. of 
events
No. of subjects 
N = 76 
n (%)
Reporting 
frequency (%)b
Congenital, familial and 
genetic disorders
Haemophiliac 1 1 (1.3) Rare (0.010)
General disorders and 
administration site 
conditions
Asthenia 1 1 (1.3) Rare (0.010)
Injection site 
discomfort
1 1 (1.3) Rare (0.010)
Infections and infestations Influenza 1 1 (1.3) Rare (0.010)
Investigations Anti factor IX 
antibody positived
1 1 (1.3) Rare (0.010)
Nervous system disorders Headache 5 2 (2.6) Rare (0.052)
Dysgeusia 1 1 (1.3) Rare (0.010)
Lethargy 1 1 (1.3) Rare (0.010)
Psychiatric disorders Apathy 1 1 (1.3) Rare (0.010)
Depression 1 1 (1.3) Rare (0.010)
Skin and subcutaneous 
tissue disorders
Rash pruritic 1 1 (1.3) Rare (0.010)
aAdverse events assessed by the study investigators as related to IB1001.
bFrequency percentage equals total number of ADRs/total number of IB1001 infusions (ie, 9629 
infusions).
cReported as exacerbation of haemophilia.
dNon- inhibitory FIX antibody.
TABLE  5 Summary of adverse drug 
reactions (ADRs)
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